Merck’s ‘COVID Pill’ Shows Promise, But Mortality Benefits Will Be Hard To Prove
Accurate Viral Test Shows Drug’s Promise
Executive Summary
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast version of Five Must-Know Things, hear about Roche's deal-making in a pandemic, coronavirus vaccine disinformation, Amgen’s Five Prime acquisition, a Novartis clinical trial failure, and new data for a Merck antiviral for the coronavirus.
Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance
Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.
Vaccitech Prepares For IPO, But AZ COVID-19 Vaccine Safety Fears Cloud Launch
The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.